CRCA vs. QTAP
CRCA (ProShares Ultra CRCL) and QTAP (Innovator Growth Accelerated Plus ETF - April) are both Leveraged Equities funds. Both are actively managed. At a 0.39 correlation, their price movements are largely independent. CRCA charges 0.95%/yr vs 0.79%/yr for QTAP.
Performance
CRCA vs. QTAP - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CRCA achieves a -25.37% return, which is significantly lower than QTAP's 14.67% return.
CRCA
- 1D
- -20.86%
- 1M
- -48.25%
- YTD
- -25.37%
- 6M
- -39.99%
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
QTAP
- 1D
- -0.10%
- 1M
- 2.89%
- YTD
- 14.67%
- 6M
- 15.56%
- 1Y
- 25.59%
- 3Y*
- 21.18%
- 5Y*
- 13.78%
- 10Y*
- —
CRCA vs. QTAP - Yearly Performance Comparison
| 2026 (YTD) | 2025 | |
|---|---|---|
CRCA ProShares Ultra CRCL | -25.37% | -81.81% |
QTAP Innovator Growth Accelerated Plus ETF - April | 14.67% | 4.69% |
Correlation
The correlation between CRCA and QTAP is 0.39, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (All Time) Calculated using the full available price history since Aug 8, 2025 | 0.39 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CRCA vs. QTAP — Risk / Return Rank
CRCA
QTAP
CRCA vs. QTAP - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra CRCL (CRCA) and Innovator Growth Accelerated Plus ETF - April (QTAP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Loading charts...
Sharpe Ratios by Period
| CRCA | QTAP | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | — | 4.62 | — |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.73 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.47 | 0.75 | -1.22 |
Drawdowns
CRCA vs. QTAP - Drawdown Comparison
The maximum CRCA drawdown since its inception was -94.02%, which is greater than QTAP's maximum drawdown of -29.44%. Use the drawdown chart below to compare losses from any high point for CRCA and QTAP.
Loading charts...
Drawdown Indicators
| CRCA | QTAP | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.02% | -29.44% | -64.58% |
Max Drawdown (1Y)Largest decline over 1 year | — | -1.69% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -13.03% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -29.44% | — |
Current DrawdownCurrent decline from peak | -87.98% | -0.10% | -87.88% |
Average DrawdownAverage peak-to-trough decline | -69.26% | -5.04% | -64.22% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 0.32% | — |
Volatility
CRCA vs. QTAP - Volatility Comparison
Loading charts...
Volatility by Period
| CRCA | QTAP | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | — | 1.33% | — |
Volatility (6M)Calculated over the trailing 6-month period | — | 3.97% | — |
Volatility (1Y)Calculated over the trailing 1-year period | 196.79% | 5.56% | +191.23% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 196.79% | 18.89% | +177.90% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 196.79% | 18.77% | +178.02% |
CRCA vs. QTAP - Expense Ratio Comparison
CRCA has a 0.95% expense ratio, which is higher than QTAP's 0.79% expense ratio.
Dividends
CRCA vs. QTAP - Dividend Comparison
CRCA's dividend yield for the trailing twelve months is around 2.32%, while QTAP has not paid dividends to shareholders.
| Position | TTM | 2025 |
|---|---|---|
CRCA ProShares Ultra CRCL | 2.32% | 1.06% |
QTAP Innovator Growth Accelerated Plus ETF - April | 0.00% | 0.00% |
Frequently Asked Questions
CRCA and QTAP have a correlation of 0.39, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, QTAP is cheaper at 0.79% per year. The better choice depends on whether you care most about return, fees, risk, or income.
QTAP is cheaper with a 0.79% expense ratio, compared with 0.95% for CRCA.
CRCA has the higher dividend yield at 2.32%, compared with 0.00% for QTAP.
They also come from different issuers: ProShares and Innovator. Their fees differ too: 0.95% for CRCA and 0.79% for QTAP.
Find the right allocation for CRCA and QTAP
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer